NEW YORK (GenomeWeb News) — LabVantage said yesterday that it has licensed its Sapphire Laboratory Information Management Suite to an undisclosed “global biopharmaceutical company” that is in the cancer and immunological disease market.
Bridgewater, NJ-based LabVantage said the biopharma will use the technology to automate their research process and establish an enterprise-wide knowledgebase of research data.  
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.